BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 19139102)

  • 1. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin-9 receptor alpha homodimers.
    Hornakova T; Staerk J; Royer Y; Flex E; Tartaglia M; Constantinescu SN; Knoops L; Renauld JC
    J Biol Chem; 2009 Mar; 284(11):6773-81. PubMed ID: 19139102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the gamma chain.
    Malka Y; Hornakova T; Royer Y; Knoops L; Renauld JC; Constantinescu SN; Henis YI
    J Biol Chem; 2008 Nov; 283(48):33569-77. PubMed ID: 18829468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
    Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
    J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor expression is essential for proliferation induced by dimerized Jak kinases.
    Fujii H
    Biochem Biophys Res Commun; 2008 Jun; 370(4):557-60. PubMed ID: 18381062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineation of the regions of interleukin-2 (IL-2) receptor beta chain important for association of Jak1 and Jak3. Jak1-independent functional recruitment of Jak3 to Il-2Rbeta.
    Zhu MH; Berry JA; Russell SM; Leonard WJ
    J Biol Chem; 1998 Apr; 273(17):10719-25. PubMed ID: 9553136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heteromerization of the gammac chain with the interleukin-9 receptor alpha subunit leads to STAT activation and prevention of apoptosis.
    Bauer JH; Liu KD; You Y; Lai SY; Goldsmith MA
    J Biol Chem; 1998 Apr; 273(15):9255-60. PubMed ID: 9535918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK kinases overexpression promotes in vitro cell transformation.
    Knoops L; Hornakova T; Royer Y; Constantinescu SN; Renauld JC
    Oncogene; 2008 Mar; 27(11):1511-9. PubMed ID: 17873904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain.
    Kirken RA; Rui H; Malabarba MG; Howard OM; Kawamura M; O'Shea JJ; Farrar WL
    Cytokine; 1995 Oct; 7(7):689-700. PubMed ID: 8580378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.
    Haan C; Rolvering C; Raulf F; Kapp M; Drückes P; Thoma G; Behrmann I; Zerwes HG
    Chem Biol; 2011 Mar; 18(3):314-23. PubMed ID: 21439476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors.
    Springuel L; Hornakova T; Losdyck E; Lambert F; Leroy E; Constantinescu SN; Flex E; Tartaglia M; Knoops L; Renauld JC
    Blood; 2014 Dec; 124(26):3924-31. PubMed ID: 25352124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinases in interleukin-2-mediated signaling: JAK1 and JAK3 are differentially regulated by tyrosine phosphorylation.
    Liu KD; Gaffen SL; Goldsmith MA; Greene WC
    Curr Biol; 1997 Nov; 7(11):817-26. PubMed ID: 9382798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon.
    Hornakova T; Chiaretti S; Lemaire MM; Foà R; Ben Abdelali R; Asnafi V; Tartaglia M; Renauld JC; Knoops L
    Blood; 2010 Apr; 115(16):3287-95. PubMed ID: 20167706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-7 signaling in human B cell precursor acute lymphoblastic leukemia cells and murine BAF3 cells involves activation of STAT1 and STAT5 mediated via the interleukin-7 receptor alpha chain.
    van der Plas DC; Smiers F; Pouwels K; Hoefsloot LH; Löwenberg B; Touw IP
    Leukemia; 1996 Aug; 10(8):1317-25. PubMed ID: 8709637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK mutations in high-risk childhood acute lymphoblastic leukemia.
    Mullighan CG; Zhang J; Harvey RC; Collins-Underwood JR; Schulman BA; Phillips LA; Tasian SK; Loh ML; Su X; Liu W; Devidas M; Atlas SR; Chen IM; Clifford RJ; Gerhard DS; Carroll WL; Reaman GH; Smith M; Downing JR; Hunger SP; Willman CL
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9414-8. PubMed ID: 19470474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling.
    Grant AH; Rodriguez AC; Rodriguez Moncivais OJ; Sun S; Li L; Mohl JE; Leung MY; Kirken RA; Rodriguez G
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.
    Degryse S; de Bock CE; Cox L; Demeyer S; Gielen O; Mentens N; Jacobs K; Geerdens E; Gianfelici V; Hulselmans G; Fiers M; Aerts S; Meijerink JP; Tousseyn T; Cools J
    Blood; 2014 Nov; 124(20):3092-100. PubMed ID: 25193870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
    Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
    Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling.
    Rutherford C; Speirs C; Williams JJ; Ewart MA; Mancini SJ; Hawley SA; Delles C; Viollet B; Costa-Pereira AP; Baillie GS; Salt IP; Palmer TM
    Sci Signal; 2016 Nov; 9(453):ra109. PubMed ID: 27919027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
    Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
    Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.